Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

1.

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.

Eisen T, Shparyk Y, Macleod N, Jones R, Wallenstein G, Temple G, Khder Y, Dallinger C, Studeny M, Loembe AB, Bondarenko I.

Invest New Drugs. 2013 Oct;31(5):1283-93. doi: 10.1007/s10637-013-9962-7. Epub 2013 Apr 27.

PMID:
23625328
[PubMed - indexed for MEDLINE]
2.

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.

Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y, Bondarenko I, Jonker DJ, Sun Y, De la Cruz JA, Williams JA, Korytowsky B, Christensen JG, Lin X, Tursi JM, Lechuga MJ, Van Cutsem E.

J Clin Oncol. 2013 Apr 1;31(10):1341-7. doi: 10.1200/JCO.2012.45.1930. Epub 2013 Jan 28.

PMID:
23358972
[PubMed - indexed for MEDLINE]
Free Article
3.

Improved survival with MEK inhibition in BRAF-mutated melanoma.

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group.

N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.

PMID:
22663011
[PubMed - indexed for MEDLINE]
Free Article
4.

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators.

N Engl J Med. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898.

PMID:
22335737
[PubMed - indexed for MEDLINE]
Free Article
5.

Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.

Vrdoljak E, Ciuleanu T, Kharkevich G, Mardiak J, Mego M, Padrik P, Petruželka L, Purkalne G, Shparyk Y, Skrbinc B, Szczylik C, Torday L.

Expert Opin Pharmacother. 2012 Feb;13(2):159-74. doi: 10.1517/14656566.2012.647406. Epub 2011 Dec 23. Review. Erratum in: Expert Opin Pharmacother. 2012 Apr;13(5):781.

PMID:
22195646
[PubMed - indexed for MEDLINE]
6.

Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.

Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M.

Clin Cancer Res. 2011 Nov 1;17(21):6822-30. doi: 10.1158/1078-0432.CCR-11-1151. Epub 2011 Aug 30.

PMID:
21878535
[PubMed - indexed for MEDLINE]
Free Article
7.

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team.

Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.

PMID:
19410716
[PubMed - indexed for MEDLINE]
8.

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.

Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group.

Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3. Epub 2009 Jan 23.

PMID:
19167925
[PubMed - indexed for MEDLINE]
9.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T.

J Clin Oncol. 2006 Dec 1;24(34):5441-7.

PMID:
17135646
[PubMed - indexed for MEDLINE]
Free Article
10.

Nature conservation in Central and Eastern Europe with a special emphasis on the Carpathian Mountains.

Oszlányi J, Grodzińska K, Badea O, Shparyk Y.

Environ Pollut. 2004 Jul;130(1):127-34.

PMID:
15046847
[PubMed - indexed for MEDLINE]
11.

Forest health status in the Carpathian Mountains over the period 1997-2001.

Badea O, Tanase M, Georgeta J, Anisoara L, Peiov A, Uhlirova H, Pajtik J, Wawrzoniak J, Shparyk Y.

Environ Pollut. 2004 Jul;130(1):93-8.

PMID:
15046844
[PubMed - indexed for MEDLINE]
12.

Heavy metal pollution and forest health in the Ukrainian Carpathians.

Shparyk YS, Parpan VI.

Environ Pollut. 2004 Jul;130(1):55-63.

PMID:
15046840
[PubMed - indexed for MEDLINE]
13.

Chemical and morphological characteristics of key tree species of the Carpathian Mountains.

Mankovská B, Godzik B, Badea O, Shparyk Y, Moravcík P.

Environ Pollut. 2004 Jul;130(1):41-54.

PMID:
15046839
[PubMed - indexed for MEDLINE]
14.

Vegetation of the selected forest stands and land use in the Carpathian Mountains.

Grodzińska K, Godzik B, Fraczek W, Badea O, Oszlányi J, Postelnicu D, Shparyk Y.

Environ Pollut. 2004 Jul;130(1):17-32.

PMID:
15046837
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk